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Abstract
In the past 30 years, the average age of biomedical researchers has steadily increased. The average age of an investigator at
the National Institutes of Health (NIH) rose from 39 to 51 between 1980 and 2008. The aging of the biomedical workforce
was even more apparent when looking at first-time NIH grantees. The average age of a new investigator was 42 in 2008,
compared to 36 in 1980. To determine if the rising barriers at NIH for entry in biomedical research might impact innovative
ideas and research, we analyzed the research and publications of Nobel Prize winners from 1980 to 2010 to assess the age at
which their pioneering research occurred. We established that in the 30-year period, 96 scientists won the Nobel Prize in
medicine or chemistry for work related to biomedicine, and that their groundbreaking research was conducted at an
average age of 41—one year younger than the average age of a new investigator at NIH. Furthermore, 78% of the Nobel
Prize winners conducted their research before the age of 51, the average age of an NIH principal investigator. This
suggested that limited access to NIH might inhibit research potential and novel projects, and could impact biomedicine and
the next generation scientists in the United States.
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Introduction
With a budget of approximately $31 billion a year, the National
Institutes of Health (NIH) (www.nih.gov) is one of the largest
granting organizations in the world. President Barack Obama
pledged in 2009 to ‘‘devote more than 3% of our GDP [gross
domesticproduct] to research and development,’’ andto specifically
‘‘promote breakthroughs in energy and medicine [1].’’ Meanwhile,
the US Congress, facing a massive budget deficit, is cutting
discretionary spending. Thus, policymakers are now more interest-
ed than ever in how NIH money is being distributed. One major
area of concern is the funding of young and first-time investigators.
NIH has been aware of the low funding rates of early-career
scientists for years. As Dr. Elias Zerhouni, NIH director from
2002-2008, remarked in a talk at the James A. Baker III Institute
for Public Policy, ‘‘you have to get a Nobel Prize before your first
grant’’—referring to Dr. David Baltimore, the 1975 Nobel Prize
winner in medicine, who received the award at the age of 37, well
under the average age of both an NIH principal investigator (PI)
and a first-time NIH grantee [2].
The average age of a PI at NIH has increased at a steady pace
from 39 in 1980 to 51 in 2008 (see Table 1) [3]. If this trend
continues, it is predicted that the number of investigators over age
70 receiving NIH grants will surpass the number under 40 in 2020
[4]. The average age of first-time grantees has also increased in the
past three decades (Figure 1). In 1980, the average age of a first-
time grant recipient was 36. By 2008, this number had increased
to 42. The age range of traditional investigator (R01-equivalent)
grantees also increased from 24–67 in 1980 to 29–85 in 2008
[3,5]. Now less than 5% of investigators are under the age of 37,
the age of Dr. Baltimore when he received the Nobel Prize,
compared to 36% in 1980. While the average age of the US
population is steadily increasing, the NIH figures (51 years in
2008) were higher than the average age of the US labor force (41
in 2008) and statistically higher than the average age of US science
and engineers faculty members (47 in 2006), even when adjusted
to 2006 data (p,0.001) [6,7].
With the increasing age of those obtaining funding from NIH,
could the United States be losing out on innovative research and
discouraging promising students from entering or continuing in
science? Previous research suggested that the aging of the
biomedical research sector will negatively impact productivity, as
younger scientists are more likely to produce high-impact
publications [8–12]. Wray argued that scientists are most
productive at mid-career, which he defined as age 36 to 45, when
they have access to more material and social resources [13,14].
This study set out to assess when innovative biomedical research
previously occurred by first establishing the age at which
pioneering ideas of Nobel Prize winners arose. The Nobel Prize
is awarded to scientists who have made the most significant
discoveries in science—discoveries that withstand the ‘‘test of
time.’’ These breakthroughs not only impact the scientists’
respective fields, but also the advancement of other areas of
science [15]. Furthermore, this prestigous award gives scientists
public recognition and affirms their standing with their peers. The
Nobel is a rare award; other awards are more limited in scope, are
less consistently awarded (i.e., not annual) or, for the purposes of
this study, do not have the database of information necessary to
track the work being honored. For these reasons, we believed it
was a good model to study.
We began our study of NIH aging trends by surveying the
publications of scientists who won the Nobel Prize in medicine or
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which the research occurred. Our results indicated that the
majority of winners were under the average age of first-time NIH
grant recipients when the Nobel-recognized research was
conducted. This suggested that the NIH might be setting high
barriers for entry into biomedical research, as demonstrated by the
rising age of PIs and first-time grantees.
Methods and Results
Nobel Laureate Age
To ascertain the age at which Nobel laureates conducted their
winning research, we first determined the project or idea that led
to the prize and matched it to a corresponding publication. The
list of recipients, obtained directly from the Nobel website, www.
nobelprize.org, included all winners from 1980 to 2010 whose
work was related to biomedical research. This consisted of all
medicine and physiology winners and a subset of chemistry
winners whose research involved DNA, RNA, or proteins. Using
the description of the research and press releases from the Nobel
website, we deduced the research topic and searched PubMed, the
online database of biomedical research (www.pubmed.org), to find
the seminal publication. We established either the specific
publication for which the award was granted (as was the case for
the 2005 award for Helicobacter pylori to Drs. Barry J. Marshall and
J. Robin Warren) or estimated when the researcher first published
his or her pioneering work (as was the case for the 2003 award to
Drs. Paul C. Lauterbur and Peter Mansfield for magnetic
resonance imaging [MRI]). The publication year determined the
age at which each winner conducted innovative research leading
to his or her award. This methodology is similar to previous studies
on Nobel laureates [16,17]. The technique might overestimate the
age of the investigator slightly since it relies on the date of
publication, which can follow the actual experiments by months or
years.
In the 30-year period studied (1980 to 2010), 96 people with
biomedical research interests were awarded the Nobel Prize. This
seemingly high total resulted from the naming of multiple winners
in each category in most years (Figure 1). Of the 96 Nobel Prize
recipients, 70 were in the field of medicine and 26 were in
chemistry. The publication age for the entire group ranged from
Figure 1. Age Comparison between NIH PIs and First-Time Recipients with Nobel Recipients, 1980- 2010. Since 1980, the average age
of an NIH principal investigator (red) and a first-time grant recipient (blue) has steadily increased. The age of principal investigators is rising faster
(with a slope of 0.42, p,.001) than first-time grant recipients (with a slope of 0.26, p,.001). Of the 96 Nobel laureates studied, 55 (57%) published
their discoveries at an age under the average age for a first-time NIH grant (blue), and 75 (78%) published before the average age for a NIH grant
(red). Ordinary least squares regression of the average age of Nobel prize winners on year of award indicated that there was no statistically significant
increase in the age over time (p=0.42). This suggested that investigators are publishing Nobel-worthy research at a younger age than a first-time NIH
grantee or the average principal investigator.
doi:10.1371/journal.pone.0029738.g001
Table 1. Range, Median and Averages of NIH PIs and First-
time Recipients and Nobel Prize Winners.
Range Median Average
New PI 1980 24 to 66 45 35.7
2008 29 to 69 49 41.6
Ave PI 1980 PI 24 to 67 45.5 39.0
2008PI 29 to 85 57 51.1
Nobel* Ave 24 to 72 41 39.9
*Average of winners from 1980 to 2008.
doi:10.1371/journal.pone.0029738.t001
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39.5 (Figure 2 and Table 1). Our study also showed that 61% of
these winners published their first research related to the Nobel
Prize work before the age of 42, the average age of first-time NIH
grant recipients in 2008. In addition, 57% were below the average
age of a first-time NIH grantee in the year they published their
groundbreaking work. For example, Dr. Carol W. Greider
received the Nobel Prize in 2009 for work she started publishing
as an approximately 24-year-old graduate student in 1985, when
the average age for a first-time NIH grant recipient was 36.8 years
old. Furthermore, 78% of the Nobel winners published their work
at an age that was younger than the overall average age for an
NIH PI (Figure 1). Ordinary least squares regression of the average
age of Nobel Prize winners on year of award indicated that there
was no statistically significant increase in age over time (p=0.42).
Nobel Laureate Funding
Once the list of laureates and their publications was generated,
the funding sources for US recipients (based on the address listed
on the publication) were determined. Of the 96 Nobel Prize
winners, 59 recipients (62% of the group) were from the United
States. Each US publication was examined for specific funding
information in the acknowledgment section of the laureate’s paper.
If possible, the NIH RePORT grant information database (http://
projectreporter.nih.gov) was searched to verify the grant and topic.
However, the database is limited to grants awarded after 1986,
and many projects were conducted prior to this date.
To confirm previous findings and obtain missing information,
we emailed each of the US laureates, when possible, asking the
question, ‘‘Could you confirm if you were being funded through
an NIH grant during the period of time you were conducting the
work that led to your Nobel Prize?’’ Some laureates were not
emailed because an address could not be obtained or they died
prior to the survey. The information obtained from the email
responses was compared to previously collected data to determine
the status of NIH funding at the time of their groundbreaking
work; the results were consistent with previous findings.
From the US group of laureates, we emailed 36 individuals and
obtained responses from 23. Using the information obtained from
the survey, their respective papers, and the NIH RePORT site, we
were able to verify the funding source for 76.3% of the US Nobel
laureates (45 of the 59). Sixteen (more than one-third) of the 45
American Nobel laureates did not receive funding from the NIH
for the early scientific work that won them the prize. The work of
seven of these recipients was funded through NIH grants, with
others listed as the PI. For instance, Dr. Carol W. Greider’s early
work was funded under Dr. Elizabeth H. Blackburn, her Ph.D.
adviser. The remaining recipients were funded through private
institutions—PEW, the March of Dimes, the American Cancer
Society, the American Heart Association, their university or a
company—or other governmental agencies, specifically the
Atomic Energy Commission or the US Public Health Service.
These results are similar to findings from other researchers who
looked at Nobel funding from 2000 to 2008 in the fields of
chemistry, physics, and medicine [18].
Discussion
As scientific research becomes more competitive, it is crucial to
fund the most promising research and promote innovative and
creative thinking. In this paper, we used the Nobel Prize as a
measure for innovation or innovative thinking to try to estimate
when novel and revolutionary ideas are formed, specifically in
biomedical research. This study suggested that Nobel Prize
winners conducted their groundbreaking research at an average
age that was lower than the average age of an NIH PI or a first-
time NIH grantee. Our data also suggested that while innovative
research can occur at any age (the Nobel researchers surveyed
ranged in age from 24 to 72 years), investigators under 40 years
old seemed to dominate the projects. While many of the young
Figure 2. Estimated Age Distribution of Biomedicine-related Nobel Recipients, 1980-2010. The estimated age distribution of the 96
laureates at time of publication of their Nobel Prize research in biomedicine ranged from 24 to 72. The average age of recipients was 41 and the
majority (61%) were under the age of 42, indicating that the distribution was not symmetric and was skewed toward younger investigators.
doi:10.1371/journal.pone.0029738.g002
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they were singled out by the Nobel committee indicated their
personal contribution was great, and the field may not have
advanced without them.
The peer-review process can be the best way to determine good
projects, but it can also be conservative and risk-averse. This can
harms both high-risk, high-impact ideas as well as new
investigators who have not established a track record. First-time
investigators are historically funded at lower rates due to their
perceived higher risk. In 2006, 14.8% of proposals from first-time
investigators received funding, compared to 17.5% for previously
funded investigators [3].
There are also other possible reasons for the lower average age
of Nobel winners compared to first-time grantees. Young
researchers might have fewer management obligations and grant
writing pressures than senior faculty members, and might
therefore spend more time in the lab on experiments. They also
have access to reagents and equipment through their mentors,
which might be missing in later stages of their careers. They could
also benefit from associating with a mature PI and receiving
increased mentoring.
In the limited survey of Nobel Prize winners, we found that in
several cases, the NIH did not fund the researchers directly for
their work leading to the award. Responses to our emails
uncovered multiple grant proposal rejections due to the research-
er’s inexperience or the peer reviewer’s reluctance to fund high-
risk projects. By raising barriers to funding, the NIH could be
stifling innovative projects by deterring young scientists from
entering the field. The NIH budget has been boosted nearly
tenfold in the past 30 years, indicating that more resources are
available and could be allocated differently to support early-career
scientists (www.nih.gov).
The American Academy of Arts and Sciences specifically
addressed high-risk, high-reward, and early-career investigators in
the publication ‘‘Advancing Research in Science and Engineering:
Investing in Early-Career Scientists and High-Risk, High-Reward
Research [19].’’ The report recommends providing seed funding that
allows early-career investigators to explore novel projects without the
requirement of preliminary results and increasing funding rates
overall. It also mentions that low grant success rates can further
discourage scientists from pursuing high-risk projects [20].
Difficulties obtaining funding can negatively impact the career
choices of young scientists, particularly in the biological sciences.
Researchers in the biological sciences are waiting longer for
independence or to start their own research projects than in other
scientific fields [21–23]. In 1973, 55% of US doctorates in
bioscience secured tenure track positions within six years of
completing their Ph.D.s; by 2006, this number dropped to 15%
[24]. After comparing faculty, nonfaculty, and postdoctoral
researchers in different areas of science and engineering, the life
sciences stand out as having the lowest percentage of Ph.D.s
employed in full-time faculty positions and the highest percentage
of postdoctoral fellows at 13.4% (Figure 3) [24]. Data from the
National Science Foundation (NSF) also indicates a growing
proportion of US Ph.D.s in postdoctoral and nontenured positions
compared to 30 years ago (Figure 4) [24]. The number of medical
and other life sciences postdoctoral positions increased 2.5 times,
from 5,200 in 1981 to 14,450 in 2006, while the number of full-
time faculty positions in the biological sciences only increased 1.6
times, from 40,900 in 1981 to 64,500 in 2006 [24]. This suggests
that potential talent vastly exceeds the number of faculty positions
available for young working scientists. Overall, close to half of all
postdoctoral positions are in the biological sciences (Figure 5) [24].
In contrast, computer science, a field known for innovation, has
the highest percentage of Ph.D.s in full-time faculty positions and
only 1.7% employed as postdoctoral fellows (Figure 3).
The lack of funding and positions also indicates that the current
American Ph.D. system might need to be reevaluated. As the 2011
Nature article ‘‘Fix the Ph.D.’’ points out, ‘‘[e]xceptionally bright
science Ph.D. holders from elite academic institutions are slogging
through five or ten years of poorly paid postdoctoral studies, slowly
becoming disillusioned by the ruthless and often fruitless fight for a
permanent academic position’’ [25]. Even outside the biological
sciences, the number of Ph.D.s in all sciences worldwide has
increased 40% between 1998 and 2008; in the United States,
many believe that this has led to a surplus of science Ph.D.s
competing for a limited number of academic positions [26–27].
This issue is amplified in the life sciences, where growth has been
the largest and is coupled, as mentioned previously, with slower
increases in the number of scientists receiving tenure. Although
many are turning to industry, the number of positions available is
not adequate to compensate for the lack of tenure-track positions;
graduate schools have not limited enrollment accordingly or
offered the training needed for alternative careers [28].
Figure 3. Science and Engineering Doctorate Holders Em-
ployed in Academia in 2006. The proportion of full-time faculty
(dark shade) was lowest for the life sciences (red) across all science and
engineering fields in 2006. The life sciences also had the highest
percentage of postdoctoral fellows (lightest shade) across all the fields.
This was in contrast to computer science (purple), which had the
highest proportion of full-time faculty and lowest proportion of
postdoctoral fellows. SOURCE: National Science Foundation, Science
and Engineering Indicators 2010.
doi:10.1371/journal.pone.0029738.g003
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over the past three years the NIH has begun to emphasize,
through the Office of the Director, the importance of finding new
ways to support young scientists and improve their chances to
obtain funding. Before leaving NIH, Dr. Zerhouni announced a
series of policies intended for new and early-stage researchers,
including grants specifically for new investigators and refining the
peer review process to help reverse the bias against first-time
grantees [3,29]. Current NIH director Dr. Francis Collins has
continued to stress that ‘‘we must liberate our brightest minds to
pursue high-risk, high-reward ideas during their most creative
years’’ [30]. To reduce barriers, he created a task force—chaired
by Dr. Shirley Tilghman, president of Princeton University—
charged with developing a model for creating a sustainable and
diverse biomedical workforce [31]. As a result of these efforts, the
NIH has shown an increase in new investigator grants. New
investigators as a percentage of grants decreased from 33.4% in
1980 to 23.9% in 2006, but recovered to 29.5% in 2009 after the
new NIH policy was implemented. Success rates have also
improved, with 18% of established investigators versus 17% of
first-time applicants receiving funding in 2010 [32].
Many of the new investigator grants were obtained through
exceptions, such as when a program officer chose a grant proposal
with a lower ranking and awarded it funding over other proposals
with better scores. In 2007, 18.5% of funded RO1 applications,
NIH’s traditional investigator grant, were exceptions, compared to
9.7% in 2003 [33]. The increase in exceptions has caused some
scientists to worry that preferential treatment is being given to some
researchers at the expense of more senior investigators, and in the
future, thesenew investigatorswill be unable tocompete atthesame
level as others who did not get preferential treatment [34].
However, NIH administration believes that the exceptions were
made by experts in their respective fields, improve an imbalance in
the system, and do not need additional monitoring or oversight.
To prevent losing bright and talented young scientists, policy-
makers need to continue to encourage NIH investment in new
investigators through increased funding of their research and by
extending more offers of faculty positions at academic institutions
[35]. Furthermore, attention should be paid to how Ph.D.
programs are managed, including monitoring the number of
students admitted each year to more effectively match the supply
with the demand for jobs [36]. Additionally, it is imperative that
NIH continues to stress the importance of supporting early-career
scientists. Ultimately, the NIH is a public entity funded by
taxpayers. The agency is responsible for demonstrating the value
of the sponsored research. Its mission is to support incremental
basic research for ‘‘fundamental knowledge about the nature and
behavior of living systems’’ as well as more high-reward and
applied projects for ‘‘the applications of knowledge to enhance
health, lengthen life, and reduce the burdens of illness and
disability’’ [37].
Figure 4. Number of Positions in the Biological Sciences, 1981–2006. The number of full-time faculty (blue) in the biological sciences has
decreased between 1981 and 2006, while the number of postdoctoral fellows (green) has increased, and number of nonfaculty full-time positions
(red) has remained relatively steady. Faculty included full-time full, associate, and assistant professors plus instructors. Nonfaculty positions included
research associates, adjunct appointments, lecturers, and administrative positions. SOURCE: National Science Foundation, Science and Engineering
Indicators 2010.
doi:10.1371/journal.pone.0029738.g004
Figure 5. Science and Engineering Postdoctoral Fellows, by
Field in 2005. Biological sciences (lightest shade) represented the
overwhelming majority of postdoctoral fellows in 2005 (49.1%)
compared to other sciences. SOURCE: National Science Foundation,
Science and Engineering Indicators 2010.
doi:10.1371/journal.pone.0029738.g005
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average age of new investigators or PIs will directly affect future
innovation or the proportion of US recipients awarded the Nobel
Prize, we do believe it could influence the number of scientists
entering and staying in biomedical research positions in academia.
To further investigate the impact of NIH’s aging trend, we believe
further research should be conducted to determine the number of
scientists leaving the field in early-career stages (i.e., between
obtaining a Ph.D. and tenure). In addition, a careful survey of the
impact of NIH’s new policy granting exceptions for new
investigators should be pursued to ascertain if these researchers
are more, less, or equally as successful as their colleagues in future
rounds of funding, when privileged status is not granted.
If nothing is done to reverse the rising age of PIs and first-time
grantees, the scientific community could lose a generation of
researchers, leading to an unsustainable biomedical research
infrastructure and a dearth of talent participating in NIH-funded
projects in the near future. In approximately 20 years, this gap will
be more apparent as senior leadership enters retirement. Without
change, biomedical research will be poised to falter as the next
generation of scientists and innovations fails to emerge. Increasing
the commitment to fund young scientists and providing career
advancement opportunities will help ensure a steady flow of
ingenuity for years to come.
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